Guardant Health, Inc. (NASDAQ:GH) headquartered in Redwood City, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website guardanthealth.com
Earnings Expectation
Guardant Health, Inc. is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.38 per share from revenue of $ 65.93 million. Looking ahead, the full year loss are expected at $ 1.6 per share on the revenues of $ 279.15 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 275.00 million ~ $ 285.00 million
Click Here For More Historical Outlooks Of Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors.
